Acute Lymphoblastic Leukemia (ALL)

First (CR1)/ Second Remission (CR2)
- Autologous or Allogeneic
  - CCT5001
    - Phase I
    - CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Recurrent/Refractory B Cell Malignancies
    - PI: Miklos Stanford
  - BMT342
    - Phase Ib/II
    - T-Cell-Depleted Graft - Conventional & Regulatory T Cells in Advanced Hematologic Malignancies
    - PI: Meyer Orca Biosystems

Advanced Disease
- Matched Related or Unrelated Donor
  - BMT340
    - Phase III
    - Tacrolimus/Methotrexate vs Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil in PBSC T
    - PI: Rezvani BMT CTN
  - BMT338
    - Phase I
    - DonorGrafts Derived From OrcaGraft w/GVHD Prophylaxis in MA-alloHCT in Hematologic Malignancies
    - PI: Meyer Orca Biosystems
  - BMT369
    - Phase II
    - MGTA-145 in Combination with Plerixafor in Hematological Malignancies
    - PI: Meyer ECOG-ACRIN

Allogeneic
- BMT339
  - CD34 Selected Allogeneic HCT w/ Myeloablative Conditioning Plus CD8+ Memory TCell Infusion in MDS&AL
  - PI: Lowsky Stanford

First (CR1) or Higher Remission
- Match Related
- Haplo
- dUCB
- BMT333 EXP
  - Phase III
  - Expanded Access Omidubicel in Allogeneic Transplantation in Hematological Malignancies
  - PI: Rezvani Gamida Cell

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Extension Study
- Trial Posting
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu